July - September 2022, Volume 18, Issue 3

Liu F, Duan JT, Teng X, Peng DQ

The Increased Plasma Levels of Intermedin in Patients with Type 2 Diabetes Mellitus

Acta Endo (Buc) 2022, 18 (3): 271-277
doi: 10.4183/aeb.2022.271

Context. Intermedin (IMD) is the member of calcitonin gene-related peptide family, and tightly associated with type 2 diabetes mellitus (T2DM). The change of plasma IMD levels in T2DM is still unknown. Objective. We aimed to investigate the plasma levels of IMD in patients with T2DM. Design. Fortyone patients with T2DM who were hospitalized in the endocrinology department of Civil Aviation General Hospital from January 2012 to June 2015 were enrolled, and 44 volunteers were selected as the control group. Subjects and Methods. Plasma level of IMD was detected by ELISA. Diagnostic value of IMD was analyzed by area under the receiver operating characteristic (ROC) curve (AUC). Results. The plasma level of IMD in T2DM group was higher than that in the healthy control group, whereas smoking or cardiovascular complications did no influence the IMD levels. IMD levels were correlated with BMI, DBP, triglyceride, uric acid, urea nitrogen, fasting and 2 hours postprandial blood glucose, and HbA1C. The greatest value of AUC for IMD was only 58.73%. Conclusions. Although plasma levels of IMD were increased in patients with T2DM, the very low diagnostic value of IMD for T2DM might not be used for the disease diagnosis.

Keywords: Intermedin, type 2 diabetes mellitus, diagnosis

Correspondence: Dingqiong Peng, Civil Aviation General Hospital, Department of Endocrinology, A-1 Gaojing Rd. Chaoyang District, Beijing, China, 100123, E-mail: dingpq@yeah.net